Part-Time
Registered Nurse
RN, Inpatient Oncology
Updated on 8/18/2026
Dana-Farber Cancer Institute
5,001-10,000 employees
Cancer treatment and research institute
Compensation Overview
$42.65 - $105.81/hr
Cambridge, MA, USA
In Person
Relocation assistance may be available for candidates moving more than 150 miles, subject to policy.
Bachelor's, Associate's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Dana-Farber Cancer Institute
See people who can refer or advise you
- An associate degree in Nursing is required; associate-degree holders must complete a Bachelor of Science in Nursing within four years.
- A current unrestricted Massachusetts Registered Nurse license is required.
- An Oncology Nursing Society/Oncology Nursing Certification Corporation Chemotherapy/Immunotherapy Certificate is required or must be obtained within six months of hire, depending on the role.
- Basic Life Support certification is required.
- Proficiency in chemotherapy and immunotherapy administration according to Oncology Nursing Society guidelines is required.
- Competence in central line care and infusion therapy, including administration and monitoring of blood products, is required.
- Ability to recognize and respond to oncologic emergencies and escalate care appropriately is required.
- Proficiency with electronic medical record systems and accurate electronic clinical documentation is required.
- Knowledge of infection prevention, hazardous drug handling under USP <800>, personal protective equipment requirements, and universal precautions is required.
- Ability to work across interdisciplinary teams and support clinical research activities is required.
- Critical thinking, clinical judgment, problem-solving, professionalism, accountability, and adherence to the American Nurses Association Code of Ethics and institutional policies are required.
- The role requires exposure to hazardous drugs and biohazards and adherence to personal protective equipment and safe handling policies.
- Deliver direct oncology nursing care, including comprehensive assessment, individualized care planning, symptom management, and evaluation of patient outcomes for adult oncology patients and families.
- Administer antineoplastic agents and supportive therapies according to protocols and Oncology Nursing Society standards; verify orders, complete independent double checks, and monitor and manage infusion reactions and adverse events.
- Manage central venous access devices, including ports and peripherally inserted central catheters; perform access, maintenance, blood draws, and blood product transfusions according to policy.
- Provide patient and family education on diagnosis, treatment plans, self-care, side-effect management, and discharge instructions; coordinate multidisciplinary resources and community referrals.
- Document care in Epic according to regulatory and institutional standards, including medication administration records, flowsheets, and patient education documentation.
- Participate in quality and safety activities, including safety huddles, infection prevention, hazardous drug handling, Joint Commission readiness, and applicable clinical research protocols.
- Collaborate with physicians, advanced practice providers, pharmacists, social workers, and research staff; contribute to team communication, handoffs, and patient throughput.
- May serve as charge nurse, preceptor, or mentor and provide functional direction to licensed and unlicensed support personnel within scope of practice and institutional policies.
- Provide direct and continuous contact to adult oncology patients and families in an inpatient environment.
- A Bachelor of Science in Nursing is strongly preferred.
- One year of recent Registered Nurse experience is preferred.
- Acute care nursing experience is preferred.
- Oncology or hematology experience in an inpatient or ambulatory infusion clinic setting is preferred.
- Experience with electronic medical records such as Epic is preferred.
- Oncology Certified Nurse certification is preferred.
- Advanced Cardiovascular Life Support certification is preferred depending on the work area.
Dana-Farber Cancer Institute provides cancer treatment and research services in Boston, serving both adult and pediatric patients. It combines patient care with a broad program of clinical trials and basic, translational, and collaborative research to advance cancer treatments. Treatments include personalized care and access to more than 700 clinical trials, aiming to tailor therapies to the patient’s tumor profile and disease type, often through targeted therapies, immunotherapy, chemotherapy, radiation, and surgical options offered at multiple treatment centers and satellite sites. The Institute differentiates itself through its affiliation with Harvard Medical School and Brigham and Women’s Hospital, its long history of cancer research breakthroughs, nationwide and international reach, and the Jimmy Fund to support patients and research. Its goal is to defeat cancer by delivering expert care while rapidly translating research discoveries into new treatments for patients everywhere.
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$54.9M
Headquarters
Boston, Massachusetts
Founded
1947
Get referred to Dana-Farber Cancer Institute
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 19, 2026 hired Sonal Gandhi to scale campus operations before hospital construction peaks.
- August 10, 2026 BJ’s campaign expands national donor visibility across 267 stores.
- August 2026 molecular-glue and myeloma programs keep Dana-Farber central to high-value translational oncology.
What critics are saying
- Dana-Farber’s 2026 $15 million False Claims Act settlement damaged grant credibility and recruiting.
- The Brigham affiliation ends in 2028, forcing disruptive clinical and staffing transitions.
- A 2031 hospital delay or cost overrun would expose Dana-Farber to capital strain.
What makes Dana-Farber Cancer Institute unique
- Dana-Farber paired its 2026 Solavia launch with NYU Langone’s Epic workflows.
- Dana-Farber advanced iberdomide from early trials to FDA approval on August 14, 2026.
- Dana-Farber is building Boston’s only dedicated adult inpatient cancer hospital, opening 2031.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↑ 15%1 year growth
↑ 15%2 year growth
↑ 15%Sonal Gandhi joins Dana-Farber as Senior Vice President for Campus Operations and Infrastructure. Posted date August 19, 2026 Dana-Farber Cancer Institute announced today that Sonal Gandhi has been hired as Senior Vice President (SVP) of Campus Operations and Infrastructure, effective August 31. In this role, Gandhi will be responsible for a broad portfolio which includes strategic oversight and excellence of facilities operations, capital construction, real estate, public safety, emergency management, employee services and operational business affairs at Dana-Farber. Additionally, Gandhi will ensure the organization's physical infrastructure, safety programs, and operational services to support the growth and long-term sustainability for the Institute. Prior to joining Dana-Farber, Gandhi served as Vice President, Real Estate, Planning and Construction for Brigham and Women's Hospital (BWH) and Faulkner Hospital. In this role, she led real estate strategy and capital planning across both facilities, including leading BWH's long-term transformation strategy for incremental inpatient capacity, research, ambulatory and administrative space optimization. "Sonal brings extensive experience leading real estate strategy, capital planning and organizational transformation across academic medicine, healthcare systems and government," said William C. Hahn, MD, PhD, Executive Vice President and Chief Operating and Transformation Officer at Dana-Farber. "We are fortunate to have the benefit of her experience, expertise and talent as we continue to advance Dana-Farber's bold vision for the future of cancer care." Gandhi spent 20 years at the Boston Planning & Development Agency in roles of increasing responsibility, where she led major economic development and intergovernmental initiatives across housing, workforce, climate and institutional growth priorities. Throughout her career, she has built strong partnerships across executive leadership, regulatory agencies and diverse stakeholders to advance bold growth visions and complex initiatives. Gandhi holds a bachelor's degree in architecture from the University of Oklahoma, a master's in urban planning from the Harvard Graduate School of Design, and is a graduate of the Advanced Management Program at Harvard Business School. Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us. Sonal Gandhi
FDA approves first CELMoD agent, with Dana-Farber helping advance its development. Posted date August 14, 2026 The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved cereblon E3 ligase modulator (CELMoD) for this disease. Researchers at Dana-Farber Cancer Institute played an important role in helping advance iberdomide to approval. Dana-Farber investigators contributed to early phase 1/2 research as part of a multi-center effort, including correlative laboratory-based work, and the institute also participated in and advised on the phase 3 clinical trial that supported the regulatory submission. Paul Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber, is a senior author on iberdomide research and served on the steering committee involved in the drug's pivotal phase 3 study and its overall development. "Dana-Farber has been deeply involved in the development of CELMoDs including iberdomide, from basic translational and clinical studies through later-stage research, all of which have helped bring this therapy earlier to US approval," said Richardson. "This approval reflects the strength of our collaborative clinical and laboratory science dedicated to real world application, and our commitment to translating promising discoveries into new treatment options for our patients with multiple myeloma." Iberdomide is an oral investigational agent designed to modulate cereblon, a key protein target central to myeloma pathobiology. The approval provides an important new treatment option for patients whose disease has returned or become resistant to prior therapies and provides a platform for its development in earlier settings. "For patients with relapsed or refractory multiple myeloma, each new effective therapy matters, especially one from a new class that may offer another path forward," said Omar Nadeem, MD, clinical director of the Myeloma Immune Cell Therapy Program at Dana-Farber. "In clinical trials, we saw that overall patients responded well to iberdomide with favorable tolerability, and this approval expands the options available as we work to achieve deeper and more durable responses for our patients." Dana-Farber continues to investigate CELMoD-based strategies in multiple myeloma, including iberdomide and its more potent partner mezigdomide, through ongoing clinical trials in relapsed/refractory disease and planned studies in newly diagnosed patients. Ongoing work includes iberdomide-based combinations aimed at improving outcomes after CAR T-cell therapy and exploring next-generation regimens earlier in treatment. Related Doctors and Researchers Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us. Paul G. Richardson, MD Omar Nadeem, MD
Dana-Farber Cancer Institute announces return of fundraising campaign by BJ's Wholesale Club. Posted date August 10, 2026 Dana-Farber Cancer Institute is pleased to announce the return of the BJ's Wholesale Club point-of-sale (POS) donation campaign in support of Dana-Farber's lifesaving mission to defy cancer. The campaign will run from Monday, August 17 through Monday, September 21, with 100% of the proceeds supporting adult and pediatric cancer care and research at Dana-Farber. BJ's donation campaign for Dana-Farber will be hosted in all 267 BJ's Wholesale Club locations. BJ's members will have the opportunity to round up the amount of their purchase to the next dollar at checkout, with the difference going directly to Dana-Farber Cancer Institute. Through this fundraising effort, BJ's and its members aim to help Dana-Farber reimagine the future of cancer care. Mariah Ponte, 7, of New Bedford, Mass., is the pediatric patient partner for this campaign. Around the holidays, Mariah experienced lower back pain. After a trip to the doctor's office and further evaluation, she was diagnosed with leukemia and spent 35 days in the hospital. Mariah began outpatient treatment at Dana-Farber Cancer Institute's Jimmy Fund Clinic in February and will continue to receive treatment for the next two years. She loves animals, playing Uno with her brothers and sisters, music, and dancing. "We would like to thank BJ's Wholesale Club for this opportunity to help advance cancer care and research for patients like Mariah," said Sheena deMedeiros, Mariah's mother. "We can't change what happened to Mariah, but if we can help because of what happened, then it's a win." "We are so grateful for BJ's support of Dana-Farber Cancer Institute with the return of this register campaign, which will span across all 267 clubs," said Melany Duval, senior vice president, chief philanthropy officer, Dana-Farber Cancer Institute. "The generosity of BJ's Wholesale Club, the leadership team, the members, and team members has helped further our mission to provide expert and compassionate care to Dana-Farber patients and advance clinical research." BJ's Wholesale Club is an active philanthropic partner to Dana-Farber Cancer Institute and the Jimmy Fund through various fundraisers and programs, resulting in significant contributions over the years. In addition to their in-club register campaign, they are also loyal sponsors of the WEEI/NESN Jimmy Fund Radio-Telethon. This year's campaign is the latest effort in the partnership between BJ's and Dana-Farber Cancer Institute that dates back to 1999. "We're excited to bring our register campaign to all 267 BJ's Wholesale Club locations this year, making it easier than ever for our members to support Dana-Farber Cancer Institute in the fight against cancer," said Bob Eddy, Chairman and Chief Executive Officer, BJ's Wholesale Club. "At BJ's, we're driven by a powerful purpose: we take care of the families who depend on us. Our partnership with Dana-Farber and our members helps bring this purpose to life by fueling research, world-class care and hope for families affected by cancer." About BJ's Wholesale Club Holdings, Inc. BJ's Wholesale Club Holdings, Inc. (NYSE: BJ) is a leading operator of membership warehouse clubs focused on delivering significant value to its members and serving a shared purpose: "We take care of the families who depend on us." The company provides a wide assortment of fresh foods, produce, a full-service deli, fresh bakery, household essentials, various exclusive offerings, gas and more to deliver unbeatable value to smart-saving families. Headquartered in Marlborough, Massachusetts, the company pioneered the warehouse club model in New England in 1984 and currently operates 267 clubs and 206 BJ's Gas(R) locations in 22 states. For more information, please visit Dana-Farber Cancer Institute, Inc. at www.BJs.com or on Facebook, or Instagram. Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.
Revolutionizing cancer treatment: Dana-Farber's breakthrough in molecular glue technology. August 9, 2026 Recent advancements in cancer research are shining a light on innovative treatment possibilities that could transform patient outcomes. A significant breakthrough has emerged from the Dana-Farber Cancer Institute, where scientists have developed a new discovery platform to identify substances known as "molecular glues." These molecular glues have the potential to create novel cancer therapies by targeting and degrading harmful proteins that drive cancer cell growth. As this research unfolds, it not only holds promise for effective cancer treatments but also highlights the critical role of artificial intelligence in accelerating oncology research. What happened at Dana-Farber? On August 6, 2026, Dana-Farber investigators announced their creation of a systematic platform designed to discover molecular glues that could be used as drug candidates for protein degradation. This exciting development builds upon prior research conducted by the Ebert and Fischer labs, which demonstrated the therapeutic potential of molecular glue degraders in cancer treatment. Molecular glues work by binding specific proteins together, leading to their degradation. In the context of cancer, many proteins can promote tumor growth if left unchecked. By utilizing these molecular glues, researchers can effectively target and eliminate these harmful proteins, potentially halting the progression of various cancers. This innovative approach is particularly significant as it opens doors to creating drugs that might be more effective and have fewer side effects than traditional therapies. Background: the importance of protein degradation in cancer treatment. Protein degradation has garnered increasing attention in cancer research due to its ability to address the underlying mechanisms of tumor growth. Certain proteins play crucial roles in cell signaling and proliferation, and their dysregulation is often a hallmark of cancer. Traditional cancer treatments, such as chemotherapy, primarily focus on killing rapidly dividing cells but can also damage healthy cells, leading to severe side effects. In contrast, molecular glue degraders offer a targeted approach by specifically identifying and degrading the proteins responsible for cancer progression. This method can potentially lead to therapies with improved efficacy and reduced toxicity. As Dana-Farber's research progresses, the hope is that new drugs will emerge that can more effectively combat various cancer types. How AI fits into cancer research and the path toward better treatments. The integration of artificial intelligence and machine learning in oncology is transforming how researchers approach drug discovery and treatment development. The process of finding effective cancer therapies is inherently complex, requiring extensive data analysis and pattern recognition. AI can streamline this process by quickly analyzing vast datasets to identify promising candidates for drug development. In the context of Dana-Farber's work on molecular glues, AI can enhance the discovery platform by predicting which molecular structures are likely to exhibit the desired binding characteristics. Machine learning algorithms can sift through existing molecular databases, quickly assessing potential candidates and their interactions, thereby significantly reducing the time it takes to bring new therapies to clinical trials. This synergy between AI and cancer research not only accelerates the drug discovery process but also paves the way for more personalized treatment approaches. By analyzing genetic and proteomic data from individual patients, researchers can tailor therapies that target specific molecular profiles, ultimately improving outcomes in precision oncology. What patients and readers should know. For cancer patients, families, and advocates, the breakthroughs at Dana-Farber are a beacon of hope in the ongoing fight against cancer. The potential for new therapies that specifically target cancer cells while sparing healthy tissues represents a significant leap forward in cancer treatment innovation. Although these research developments are still in the early stages, they underscore the importance of continued investment in cancer research and the need for ongoing education about emerging therapies. As the landscape of cancer treatment evolves, staying informed about the latest advancements is crucial. At curecancerwithai.com, Cure Cancer With AI provide a comprehensive resource for understanding the intersection of artificial intelligence and cancer research. Its platform offers updates, educational materials, and insights into how AI is shaping the future of oncology. While Cure Cancer With AI do not provide medical advice, Cure Cancer With AI aim to empower patients and supporters with knowledge about the advancements in cancer treatment and research. Conclusion: A bright future for cancer research. The work being done at Dana-Farber Cancer Institute represents a significant advancement in the search for effective cancer treatments. By harnessing the power of molecular glues and integrating artificial intelligence into their research, scientists are paving the way for innovative therapies that could transform patient care. As Cure Cancer With AI continue to learn more about these developments, it is essential for cancer patients and their advocates to stay informed and engaged. Together, Cure Cancer With AI can support the ongoing quest for better cancer treatments and ultimately, a cure. For the latest updates and resources, visit curecancerwithai.com, your trusted source for information on AI and cancer research.
Revolutionizing cancer treatment: Dana-Farber's breakthrough in molecular glue degraders. August 9, 2026 The recent announcement from Dana-Farber Cancer Institute about the development of a new protein degrader discovery platform marks a significant milestone in the quest for innovative cancer treatments. This research is crucial not only for the scientific community but also for cancer patients and their families, as it opens doors to novel therapies that could offer more effective and targeted options. The focus on molecular glues - substances that can facilitate the degradation of harmful proteins driving cancer - could redefine the landscape of cancer treatment, making it more precise and less harmful to healthy cells. What happened at Dana-Farber? Researchers at Dana-Farber have unveiled a groundbreaking method for identifying molecular glues, which are capable of targeting specific proteins that contribute to cancer progression. These proteins often play a role in the uncontrolled growth of cancerous cells. By leveraging a systematic discovery platform, the team aims to create new drug candidates that utilize these molecular glues to degrade problematic proteins effectively. This recent advancement builds on the earlier research conducted by the Ebert and Fischer labs, which highlighted the potential of molecular glue degraders in cancer therapy. The implications of this work could be profound, allowing for the development of therapies that are not only more effective but also have the potential to produce fewer side effects than traditional cancer treatments. Background: the importance of protein degradation in cancer. Cancer is often driven by proteins that promote abnormal cell growth and survival. The ability to target and degrade these proteins is a critical goal in cancer research. Traditional approaches, such as chemotherapy and radiation, often affect both cancerous and healthy cells, leading to significant side effects. In contrast, the strategy of using molecular glues to selectively degrade harmful proteins could pave the way for more precise oncology treatments, significantly improving patient outcomes. By focusing on molecular glues, researchers can develop drugs that act in a more targeted manner - attacking only the proteins that contribute to cancer while sparing the healthy ones. This precision could lead to treatments that are not only effective but also less toxic for patients. How AI fits into cancer research and the path toward better treatments. The integration of artificial intelligence (AI) and machine learning into cancer research is transforming how scientists approach drug discovery and treatment development. AI technologies can analyze vast datasets, identify patterns, and predict how various compounds will interact with biological systems. In the context of Dana-Farber's research, AI could play a crucial role in optimizing the discovery of molecular glues and facilitating the identification of the most promising drug candidates. Accelerating drug discovery. Machine learning algorithms can help researchers rapidly sift through existing data to identify potential molecular glue candidates. This capability is particularly important as the complexity of cancer biology makes traditional experimental methods time-consuming and costly. By employing AI, scientists can expedite the process of drug discovery, leading to quicker development of new therapies and potentially saving lives in the process. Precision and personalization. AI can also contribute to the field of precision oncology, where treatments are tailored to the individual characteristics of a patient's tumor. By leveraging AI algorithms to analyze genetic and molecular profiles, researchers can identify which patients are most likely to benefit from specific molecular glue degraders. This personalized approach could enhance treatment efficacy and minimize unnecessary side effects, improving the overall quality of life for cancer patients. What patients and readers should know. For patients, families, and advocates, the developments at Dana-Farber exemplify the ongoing evolution of cancer treatment. While the research is still in its early stages, the promise of molecular glue degraders could lead to new therapies that are not only more effective but also tailored to the unique needs of individual patients. It is important to remember that these advancements are part of a broader landscape of cancer research and treatment innovation. As these discoveries progress, staying informed about the latest breakthroughs and understanding their implications can empower patients and their families in their treatment journeys. At curecancerwithai.com, Cure Cancer With AI provide a comprehensive resource for cancer patients and advocates to learn about the intersection of artificial intelligence and cancer research. Its mission is to keep you updated on the latest developments in AI cancer research, ensuring that you have access to trustworthy information as the field continues to evolve. Conclusion. The recent advancements in molecular glue degraders at Dana-Farber Cancer Institute highlight a promising new frontier in cancer treatment. By harnessing the power of AI and innovative drug discovery platforms, researchers are paving the way for therapies that could transform the lives of countless cancer patients. Staying informed about these changes is vital, and resources like curecancerwithai.com serve as a valuable tool for those seeking the latest information in this rapidly advancing field.